Literature DB >> 17053897

Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction.

Melinda Wuest1, Anke Weiss, Magali Waelbroeck, Manfred Braeter, Lutz-Ullrich Kelly, Oliver W Hakenberg, Ursula Ravens.   

Abstract

Propiverine is a commonly used antimuscarinic drug used as therapy for symptoms of an overactive bladder. Propiverine is extensively biotransformed into several metabolites that could contribute to its spasmolytic action. In fact, three propiverine metabolites (M-5, M-6 and M-14) have been shown to affect various detrusor functions, including contractile responses and L-type calcium-currents, in humans, pigs and mice, albeit with different potency. The aim of our study was to provide experimental evidence for the relationship between the binding of propiverine and its metabolites to human muscarinic receptor subtypes (hM(1)-hM(5)) expressed in chinese hamster ovary cells, and to examine the effects of these compounds on muscarinic receptor-mediated detrusor function. Propiverine, M-5, M-6 and M-14 bound to hM(1)-hM(5) receptors with the same order of affinity for all five subtypes: M-6 > propiverine > M-14 > M-5. In HEK-293 cells expressing hM(3), carbachol-induced release of intracellular Ca(2+) ([Ca(2+)](i)) was suppressed by propiverine and its metabolites; the respective concentration-response curves for carbachol-induced Ca(2+)-responses were shifted to the right. At higher concentrations, propiverine and M-14, but not M-5 and M-6, directly elevated [Ca(2+)](i). These results were confirmed for propiverine in human detrusor smooth muscle cells (hDSMC). Propiverine and the three metabolites decreased detrusor contractions evoked by electric field stimulation in a concentration-dependent manner, the order of potency being the same as the order of binding affinity. We conclude that, in comparison with the parent compound, loss of the aliphatic side chain in propiverine metabolites is associated with higher binding affinity to hM(1)-hM(5) receptors and higher functional potency. Change from a tertiary to a secondary amine (M-14) results in lower binding affinity and reduced potency. Oxidation of the nitrogen (M-5) further lowers binding affinity as well as functional potency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053897     DOI: 10.1007/s00210-006-0103-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  41 in total

Review 1.  Potential therapeutic targets for treatment of the overactive bladder.

Authors:  D J Sellers; C R Chapple; R Chess-Williams
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

2.  Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing.

Authors:  Kylie J Mansfield; Lu Liu; Frederick J Mitchelson; Kate H Moore; Richard J Millard; Elizabeth Burcher
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

3.  P2X receptors and their role in female idiopathic detrusor instability.

Authors:  Barry A O'Reilly; Alan H Kosaka; Gillian F Knight; Thomas K Chang; Anthony P D W Ford; Janice M Rymer; Rick Popert; Geoffrey Burnstock; Stephen B McMahon
Journal:  J Urol       Date:  2002-01       Impact factor: 7.450

4.  Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction.

Authors:  Melinda Wuest; Juliane Hecht; Torsten Christ; Manfred Braeter; Christian Schoeberl; Oliver W Hakenberg; Manfred P Wirth; Ursula Ravens
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

5.  Pharmacological effects of tolterodine on human isolated urinary bladder.

Authors:  M Yono; M Yoshida; Y Wada; H Kikukawa; W Takahashi; A Inadome; H Seshita; S Ueda
Journal:  Eur J Pharmacol       Date:  1999-03-05       Impact factor: 4.432

Review 6.  Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder.

Authors:  Christopher R Chapple
Journal:  Expert Opin Investig Drugs       Date:  2004-11       Impact factor: 6.206

7.  Cholinergic and purinergic responses in isolated human detrusor in relation to age.

Authors:  Melinda Wuest; Kathrin Morgenstern; Eva-Maria Graf; Manfred Braeter; Oliver W Hakenberg; Manfred P Wirth; Ursula Ravens
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

8.  Extracts from Rhois aromatica and Solidaginis virgaurea inhibit rat and human bladder contraction.

Authors:  Verena E Borchert; Peter Czyborra; Charlotte Fetscher; Mark Goepel; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-13       Impact factor: 3.000

9.  Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations.

Authors:  A Haruno
Journal:  Arzneimittelforschung       Date:  1992-06

Review 10.  Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

Authors:  K-E Andersson; M Yoshida
Journal:  Eur Urol       Date:  2003-01       Impact factor: 20.096

View more
  13 in total

Review 1.  Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?

Authors:  Martin C Michel; Sharath S Hegde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11       Impact factor: 3.000

Review 2.  [Drug-drug interactions in urology].

Authors:  M C Michel; R F Schäfers; J J M C H de la Rosette
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

Review 3.  Urothelial effects of oral agents for overactive bladder.

Authors:  Karl-Erik Andersson; Claudius Fullhase; Roberto Soler
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

4.  Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine.

Authors:  Stefan Propping; Manfred Braeter; Marc-Oliver Grimm; Manfred P Wirth; Ursula Ravens; Melinda Wuest
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-02-25       Impact factor: 3.000

5.  Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder.

Authors:  Werner Siegmund; Ulla Sillén; Göran Läckgren; Frieder Schnabel; Gerd Mürtz; Cornelia Feustel
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

6.  Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination.

Authors:  Karen May; Thomas Giessmann; Danilo Wegner; Reinhard Oertel; Christiane Modess; Stefan Oswald; Manfred Braeter; Werner Siegmund
Journal:  Eur J Clin Pharmacol       Date:  2008-07-15       Impact factor: 2.953

Review 7.  Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.

Authors:  Kate McKeage
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

8.  In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.

Authors:  Shuji Maruyama; Naoki Hasuike; Kazuhiro Suzuki; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-12       Impact factor: 3.000

9.  Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes.

Authors:  Hai-Lei Zhu; Keith L Brain; Manami Aishima; Atsushi Shibata; John S Young; Katsuo Sueishi; Noriyoshi Teramoto
Journal:  J Pharmacol Exp Ther       Date:  2007-10-10       Impact factor: 4.030

10.  Electrophysiological profile of propiverine--relationship to cardiac risk.

Authors:  Torsten Christ; Erich Wettwer; Melinda Wuest; Manfred Braeter; Frank Donath; Pascal Champeroux; Serge Richard; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.